[HTML][HTML] Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions
KM Sullivan, FA Farraye, KL Winthrop, DO Willer… - Vaccine, 2023 - Elsevier
Compared with the general population, older adults with immune senescence and
individuals who are immunocompromised (IC) due to disease or immunosuppressive …
individuals who are immunocompromised (IC) due to disease or immunosuppressive …
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
G Reynolds, VG Hall, BW Teh - Transplant Infectious Disease, 2023 - Wiley Online Library
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
How I prevent viral reactivation in high-risk patients
SS Dadwal, GA Papanicolaou… - Blood, The Journal of …, 2023 - ashpublications.org
Preventing viral infections at an early stage is a key strategy for successfully improving
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
EA Stadtmauer, KM Sullivan, M El Idrissi… - Human vaccines & …, 2021 - Taylor & Francis
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant
(auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth …
(auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth …
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
A Mwakingwe-Omari, N Lecrenier, A Naficy… - Human Vaccines & …, 2023 - Taylor & Francis
Herpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-
mediated immunity, as observed with aging and immunosuppressive disorders and …
mediated immunity, as observed with aging and immunosuppressive disorders and …
Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation
E Baumrin, NE Izaguirre, B Bausk, MM Feeley… - Blood …, 2021 - ashpublications.org
Allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk for
varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted …
varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted …
Cellular immune response after vaccination with an adjuvanted, recombinant zoster vaccine in allogeneic hematopoietic stem cell transplant recipients
M Koldehoff, PA Horn, M Lindemann - Vaccines, 2022 - mdpi.com
Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary
varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection …
varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection …
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a …
JK Park, M Kim, JI Jung, JY Kim, H Jeong… - The Lancet …, 2024 - thelancet.com
Background The adjuvanted herpes zoster subunit vaccine has shown good efficacy and
safety in the general population. However, its effectiveness has not been comprehensively …
safety in the general population. However, its effectiveness has not been comprehensively …
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: looking forward as the network celebrates its 20th year
In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations
of 11 committees concerning major topics pertinent to a particular disease, modality, or …
of 11 committees concerning major topics pertinent to a particular disease, modality, or …
[HTML][HTML] Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation
AL Olson, I Politikos, C Brunstein, F Milano… - … and Cellular Therapy, 2021 - Elsevier
As an alternative stem cell source, cord blood (CB) has many advantages. However,
delayed engraftment, lack of transferred immunity, and a significant incidence of acute graft …
delayed engraftment, lack of transferred immunity, and a significant incidence of acute graft …